Evidence map›Paper›PMID 39518004›Full record

ArticleCancers2024

Optimizing Treatment Strategies for

Quentin Dominique Thomas, Nicolas Girard, Lise Bosquet, Sarah Cavaillon, Thomas Filleron, Siham Eltaief, Christos Chouaid, Hervé Lena, Didier Debieuvre, Maurice Perol and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03848052 (Epidemiological Strategy and Medical Economic), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03848052 recruitingnot on this map

Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015

TypeobservationalSponsorUNICANCERRan2017 to 2026Enrolled75,000ConditionsLung Cancer
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Quentin Dominique ThomasDepartment of Medical Oncology, Institut du Cancer de Montpellier, 34000 Montpellier, France.ORCID 0000-0001-9516-9797
Nicolas GirardDepartment of Medical Oncology, Institut Curie, 75005 Paris, France.
Lise BosquetUnicancer, 75000 Paris, France.ORCID 0000-0001-5100-9425
Sarah CavaillonDepartment of Medical Oncology, Institut du Cancer de Montpellier, 34000 Montpellier, France.
Thomas FilleronBiostatistics Unit, Oncopôle Claudius Régaud IUCT-O, 31100 Toulouse, France.ORCID 0000-0003-0724-0659
Siham EltaiefUnicancer, 75000 Paris, France.
Christos ChouaidDepartment of Pneumology, Centre Hospitalier Intercommunal, 94010 Créteil, France.ORCID 0000-0002-4290-5524
Hervé LenaPneumology Department, CHU Pontchaillou, 35000 Rennes, France.
Didier DebieuvreRespiratory Medicine Department, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, 68100 Mulhouse, France.ORCID 0000-0002-8016-7956
Maurice PerolDepartment of Medical Oncology Centre Léon Bérard, 69008 Lyon, France.
Xavier QuantinDepartment of Medical Oncology, Institut du Cancer de Montpellier, 34000 Montpellier, France.ORCID 0000-0002-5403-3612

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

brain metastasisEGFR mutationnon-small-cell lung cancertreatment sequencingtyrosine kinase inhibitors

Identifiers

PMID39518004
PMCPMC11545234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.